©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessCYP2D6 analysis before Tamoxifen therapy

Summary

Short information

The speed of the metabolization by CYP450 2D6 co-determines the parmacologocal level in the Tamoxifen therapy. The genetic CYP2D6 variants are determined in a curated manner.

ID
PT7531
Number of genes
1 Accredited laboratory test
Examined sequence length
1,5 kb (Core-/Core-canditate-Genes)
- (Extended panel: incl. additional genes)
Analysis Duration
on request
Material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

Sanger

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GHeredity
CYP2D61494AR

Informations about the disease

Clinical Comment

illness_clinical_commment_PT7531

 

Synonyms
  • Allelic: Cerdelga-Therapie - Morbus Gaucher
  • Allelic: Codeine sensitivity
  • Allelic: Debrisoquine sensitivity
  • Cytochrom P450 2D6
  • Fremdsubstanz-Metabolisierer (Opiode, trizyklische Antidepressiva, Neuroleptika, Beta-Blocker etc.)
  • Poor and/or ultrarapid metabolism of several drugs, including debrisoquine, sparteine, nortriptyline
Heredity, heredity patterns etc.
  • AR
OMIM-Ps
ICD10 Code
Z51.-

Bioinformatics and clinical interpretation

No text defined